Compared with the pedHGG_H3-/IDH-wt subtype (median OS: 15.2 months [Q1–Q3: 10.9–23.7]), IDH1-mutant gliomas showed prolonged survival (median OS: 54.6 months [Q1–Q3: 27.7–131.2]), whereas the number of cases is too small to draw a statistical conclusion (Figure 6B). Here, IDH1 is linked to glioma.